Diadexus, OriGene deal

Diadexus granted OriGene exclusive rights to develop and commercialize Diadexus’ PLAC ELISA test in undisclosed Asian countries. OriGene purchased $1 million in diaDexus stock at about $3.82 per share, which is about a 27% premimum to Diadexus’ closed at $3.01 on Sept. 4, the last trading day before the deal was announced. Diadexus will supply OriGene materials and reagents for PLAC ELISA on a cost plus profit basis. Diadexus is eligible for sales milestones and mid-single-digit royalties. ...